An interventional study of Eye examinations and Questionnaire in Rod Cone Dystrophy, sponsored by SparingVision. Recruiting at 3 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by SparingVision · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
ECSTASI is a Natural History Study, which will be monitoring how standard of care (SoC) affect advanced rod-cone dystrophy (RCD), a type of eye disease also known as retinitis pigmentosa. No experimental, investigational or any other drug or treatment will be tested during the study.
This study collects information in 3 parts:
Part 1: retrospective health information from medical records (up to past 10 years), Part 2: prospective health information from in-person visits (up to 1 year), and Part 3: prospective health information from medical records (up to 1 year). Participants will decide if they wish to participate in all or only to some of these parts.
40 studies on the registry are indexed under Cone-Rod Dystrophies; 15 are open to participants now.
This study's planned enrollment of 100 is above the median of 28 across 28 interventional studies indexed under Cone-Rod Dystrophies.
Browse Cone-Rod Dystrophies studies →SparingVision is the lead sponsor of 5 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This Natural History study is designed as a combination of prospective and retrospective evaluations in patients diagnosed with advanced RCD. Prospective data will be collected during in-person study visits and/or SoC routine eye examinations (not planned per protocol) as they are reported in the medical records of the participant for up to 1 year after study enrollment. Retrospective data will be collected from the medical records of the participant for up to 10 years before enrollment.
Other: Eye examinations · Other: Questionnaire
Routine eye examinations (including slit lamp exam and dilated fundus exam), standard visual assessments (such as best corrected visual acuity test and ocular coherence tomography), evaluation of visual function (such as microperimetry).
Patient-reported quality of life questionnaire.
Best-corrected visual acuity (BCVA)
Change in BCVA from Baseline to Month 6
Time frame: At 6 months
To evaluate the effects of SoC on visual function at 1 year of follow up
Change in BCVA from baseline to Year 1
Time frame: At 1 year
To determine the precision and reliability of the assessments of visual function measured in ECSTASI
Test-retest variability and signal-to-noise ratio of visual function measurements such as BCVA and microperimetry.
Time frame: 1 year
To evaluate participant potential eligibility for the Phase 1/2a clinical trial of SPVN20 (NYRVANA).
Percentage of participants potentially eligible to participate in the Phase 1/2a clinical trial of SPVN20 (NYRVANA), based on data collected in the ECSTASI study.
Time frame: 1 year
To evaluate the effects of SOC on visual function at 6 months and 1 year of follow-up for FST
Change in FST from baseline to Month 6 and Year 1
Time frame: 1 year
To evaluate the effects of SOC on visual function at 6 months and 1 year of follow-up for microperimetry
Change in microperimetry foveal sensitivity from baseline to Month 6 and Year 1
Time frame: 1 year
To evaluate the effects of SOC on visual function at 6 months and 1 year of follow-up for eye dominance
Change in eye dominance from baseline to Month 6 and Year 1
Time frame: 1 year
Plan to share: Undecided
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for Sep 2028, 24 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
SparingVision